Tipranavir
- Generic Name
- Tipranavir
- Brand Names
- Aptivus
- Drug Type
- Small Molecule
- Chemical Formula
- C31H33F3N2O5S
- CAS Number
- 174484-41-4
- Unique Ingredient Identifier
- ZZT404XD09
- Background
Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
- Indication
For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 997
- Registration Number
- NCT00146328
- Locations
- 🇺🇸
1182.17.26 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
🇺🇸1182.17.89 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇺🇸1182.17.73 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
- Conditions
- HIV Infections
- Interventions
- Drug: Comparator protease inhibitor(CPI)/low dose ritonavir(r)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 882
- Registration Number
- NCT00144170
- Locations
- 🇲🇽
1182.48.5202 Hospital Lopez Mateos, Mexico, Mexico
🇵🇹1182.48.3505 Hospital Egas Moniz, Lisboa, Portugal
🇲🇽1182.48.5201 Centro Médico La Raza IMSS, Mexico, D.F., Mexico
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
- Conditions
- HIV Infections
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00097799
- Locations
- 🇺🇸
1182.70.066, Los Angeles, California, United States
🇺🇸1182.70.174, Macon, Georgia, United States
🇺🇸1182.70.071, Los Angeles, California, United States
Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00062660
- Locations
- 🇺🇸
1182.58.20 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸1182.58.18 University of Texas Southwest Medical Center at Dallas, Dallas, Texas, United States
🇦🇺1182.58.61012 Bigge Park Centre, Liverpool, New South Wales, Australia
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2003-03-21
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 328
- Registration Number
- NCT00056641
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇩🇪Boehringer Ingelheim Investigational Site, Stuttgart, Germany
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2003-02-10
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 630
- Registration Number
- NCT00054717
- Locations
- 🇺🇸
1182.12.9 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇺🇸1182.12.7 Boehringer Ingelheim Investigational Site, Norwalk, Connecticut, United States
🇺🇸1182.12.1 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.